Innate Pharma SA
NASDAQ:IPHA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Innate Pharma SA
NASDAQ:IPHA
|
FR |
|
Scandinavian Tobacco Group A/S
CSE:STG
|
DK |
|
Wintrust Financial Corp
NASDAQ:WTFC
|
US |
|
Aegis Brands Inc
TSX:AEG
|
CA |
|
B
|
Bangkok Dusit Medical Services PCL
SET:BDMS
|
TH |
|
W
|
Warrix Sport PCL
SET:WARRIX
|
TH |
|
9F Inc
NASDAQ:JFU
|
CN |
|
A
|
Alla PCL
SET:ALLA
|
TH |
|
Singapore Shipping Corporation Ltd
SGX:S19
|
SG |
|
M
|
Mad Paws Holdings Ltd
ASX:MPA
|
AU |
|
F
|
Foxtons Group PLC
XMUN:FXG
|
UK |
Wall St Price Targets
IPHA Price Targets Summary
Innate Pharma SA
According to Wall Street analysts, the average 1-year price target for IPHA is 6.19 USD with a low forecast of 5.15 USD and a high forecast of 7.38 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is IPHA's stock price target?
Price Target
6.19
USD
According to Wall Street analysts, the average 1-year price target for IPHA is 6.19 USD with a low forecast of 5.15 USD and a high forecast of 7.38 USD.
What is the Revenue forecast for Innate Pharma SA?
Projected CAGR
92%
Over the last 14 years, the compound annual growth rate for Revenue has been -7%. The projected CAGR for the next 7 years is 92%.
What is the Gross Profit forecast for Innate Pharma SA?
Projected CAGR
1 086%
The compound annual growth rate for Gross Profit over the next 3 years is 1 086%.
